Dec. 8 at 9:57 PM
$ASMB likely
$GILD opt-in news very soon
To “opt-in” Gilead must pay an opt-in fee of at least US
$45 million per program (after clinical proof-of-concept is demonstrated).
If Gilead exercises the option:
Assembly Bio becomes eligible to receive up to US
$330 million per program in regulatory and commercial milestone payments (on top of the opt-in fee).
In addition, Assembly Bio would earn royalties on net sales — ranging from the high single digits to high teens (percent).
For U.S. commercialization, Assembly Bio retains the option to co-promote (i.e., share in profits/costs) rather than just passively receive royalties — meaning they could take a more active commercial role in the U.S. market.
Beyond opt-in and milestones, the agreement includes collaboration-extension payments: Assembly Bio may receive up to three separate US
$75 million extension payments at pre-specified timepoints, to support continued R&D under the partnership’s umbrella.
